- MenB —
- serogroup B meningococcal
Meningococcal infections can be fulminant and result in death only a few hours after symptom onset. The mortality rate ranges between 10% and 15%, and those who survive can have severe sequelae.1 Globally, it is estimated that 1.2 million cases of invasive meningococcal infections occur annually and result in 135 000 deaths.2
Primary prevention of disease through vaccination is essential for control of endemic and epidemic meningococcal disease. Serogroup B meningococcal (MenB) infections account for 65% of cases in infants in the United States (incidence: 3.3 cases per 100 000) and the majority of cases overall in some European countries, including England.2 In 2014 and 2015, 2 recombinant MenB vaccines were licensed in the United States for individuals 10 to 25 years of age.2 MenB vaccines are currently recommended routinely for high-risk groups in the appropriate age category (Category A recommendation) and may be considered in adolescents and young adults (Category B recommendation).
In this issue of Pediatrics, Mbaeyi et al3 used the enhanced meningococcal disease …
Address correspondence to Lucila Marquez, MD, MPH, Department of Pediatrics, Baylor College of Medicine, 1102 Bates Ave, Suite 1150, Houston, TX 77030. E-mail: